401 is the total number of securities RA Capital Management has owned. The longest RA Capital Management has owned a single stock is 35 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
ASND | ASCENDIS PHARMA A/S - ADR | 35 | 35 | 1.76% | 15.13% | 25.54% | Q1 2015 | Q3 2023 | 35 |
WVE | WAVE LIFE SCIENCES PTE... | 32 | 32 | 0.34% | 9.48% | 26.26% | Q4 2015 | Q3 2023 | 32 |
TGTX | TG THERAPEUTICS INC | 16 | 1 | 0.32% | 3.06% | 6.32% | Q3 2013 | Q4 2021 | 30 |
ZGNX | ZOGENIX INC | 26 | 26 | 0.70% | 3.36% | 9.55% | Q3 2015 | Q4 2021 | 26 |
BCRX | BIOCRYST PHARMACEUTICALS | 23 | 23 | 1.08% | 3.68% | 9.21% | Q3 2013 | Q1 2019 | 23 |
DRNA | DICERNA PHARMACEUTICAL... | 23 | 23 | 0.88% | 2.69% | 5.80% | Q1 2014 | Q3 2019 | 23 |
RYTM | RHYTHM PHARMACEUTICALS... | 22 | 22 | 0.54% | 2.24% | 4.40% | Q2 2018 | Q3 2023 | 22 |
ACHN | ACHILLION PHARMACEUTIC... | 19 | 19 | 0.14% | 8.65% | 17.21% | Q2 2013 | Q4 2017 | 19 |
KALA | KALA PHARMACEUTICALS INC | 19 | 19 | 0.23% | 1.58% | 4.36% | Q3 2017 | Q1 2022 | 19 |
SLDB | SOLID BIOSCIENCES INC | 19 | 19 | 0.12% | 1.55% | 6.78% | Q1 2018 | Q3 2022 | 19 |
SCPH | SCPHARMACEUTICALS INC | 18 | 1 | 0.24% | 0.76% | 2.89% | Q4 2017 | Q4 2022 | 19 |
SGMO | SANGAMO THERAPEUTICS INC | 14 | 2 | 0.43% | 2.86% | 8.46% | Q2 2013 | Q3 2017 | 16 |
ETNB | 89BIO INC | 16 | 16 | 0.41% | 1.98% | 4.08% | Q4 2019 | Q3 2023 | 16 |
ARDX | ARDELYX INC | 8 | 7 | 0.56% | 1.78% | 4.36% | Q2 2015 | Q2 2021 | 15 |
ORTX | ORCHARD THERAPEUTICS PLC | 15 | 15 | 0.05% | 1.70% | 4.44% | Q4 2018 | Q2 2022 | 15 |
STSA | SATSUMA PHARMACEUTICAL... | 15 | 15 | 0.09% | 1.17% | 4.19% | Q3 2019 | Q1 2023 | 15 |
PRTO | PROTEON THERAPEUTICS INC | 8 | 7 | 0.14% | 1.15% | 3.01% | Q4 2014 | Q4 2018 | 15 |
KALV | KALVISTA PHARMACEUTICA... | 10 | 5 | 0.14% | 0.84% | 1.78% | Q4 2016 | Q1 2022 | 15 |
BDTX | BLACK DIAMOND THERAPEU... | 15 | 15 | 0.09% | 0.66% | 2.13% | Q1 2020 | Q3 2023 | 15 |
RARX | RA PHARMACEUTICALS INC | 14 | 14 | 0.96% | 3.93% | 7.37% | Q4 2016 | Q1 2020 | 14 |
PCVX | VAXCYTE INC | 14 | 14 | 1.15% | 3.56% | 7.92% | Q2 2020 | Q3 2023 | 14 |
IMGN | IMMUNOGEN INC | 13 | 1 | 0.46% | 1.94% | 4.16% | Q1 2020 | Q3 2023 | 14 |
GERN | GERON CORP | 14 | 14 | 0.57% | 1.09% | 1.93% | Q2 2020 | Q3 2023 | 14 |
CNCE | CONCERT PHARMACEUTICAL... | 12 | 2 | 0.13% | 0.37% | 1.00% | Q1 2015 | Q4 2022 | 14 |
TXMD | THERAPEUTICSMD INC | 10 | 3 | 0.13% | 2.35% | 7.08% | Q2 2013 | Q2 2021 | 13 |
ITOS | ITEOS THERAPEUTICS INC | 13 | 13 | 0.95% | 2.00% | 3.63% | Q3 2020 | Q3 2023 | 13 |
NKTX | NKARTA INC | 13 | 13 | 0.21% | 1.96% | 4.82% | Q3 2020 | Q3 2023 | 13 |
VRNA | VERONA PHARMA PLC - ADR | 13 | 13 | 0.39% | 1.26% | 3.35% | Q3 2020 | Q3 2023 | 13 |
MYOV | MYOVANT SCIENCES LTD | 12 | 12 | 1.91% | 3.56% | 4.90% | Q4 2016 | Q3 2019 | 12 |
AXSM | AXSOME THERAPEUTICS INC | 10 | 2 | 0.80% | 1.93% | 3.54% | Q1 2019 | Q3 2023 | 12 |
DYAX | DYAX CORP | 11 | 11 | 1.42% | 6.95% | 10.12% | Q2 2013 | Q4 2015 | 11 |
ACRS | ACLARIS THERAPEUTICS INC | 7 | 4 | 0.59% | 2.86% | 6.84% | Q4 2015 | Q3 2023 | 11 |
VOR | VOR BIOPHARMA INC | 11 | 11 | 0.94% | 2.48% | 7.23% | Q1 2021 | Q3 2023 | 11 |
BIIB | BIOGEN INC | 7 | 4 | 0.10% | 2.27% | 5.34% | Q3 2014 | Q3 2023 | 11 |
MGNX | MACROGENICS INC | 8 | 1 | 0.03% | 1.50% | 2.56% | Q4 2013 | Q3 2023 | 11 |
CNTB | CONNECT BIOPHARMA HOLD... | 11 | 11 | 0.11% | 0.67% | 2.35% | Q1 2021 | Q3 2023 | 11 |
EYPT | EYEPOINT PHARMACEUTICA... | 11 | 11 | 0.18% | 0.47% | 0.89% | Q1 2021 | Q3 2023 | 11 |
FMTX | FORMA THERAPEUTICS HLD... | 10 | 10 | 1.66% | 4.07% | 8.22% | Q2 2020 | Q3 2022 | 10 |
EIDX | EIDOS THERAPEUTICS INC | 10 | 10 | 1.15% | 3.32% | 6.05% | Q2 2018 | Q3 2020 | 10 |
NVAX | NOVAVAX INC | 10 | 10 | 0.16% | 3.18% | 6.84% | Q2 2013 | Q3 2015 | 10 |
AVTE | AEROVATE THERAPEUTICS INC | 10 | 10 | 1.72% | 3.04% | 4.91% | Q2 2021 | Q3 2023 | 10 |
CCXI | CHEMOCENTRYX INC | 8 | 1 | 0.05% | 2.95% | 5.41% | Q3 2013 | Q1 2022 | 10 |
ARVN | ARVINAS INC | 10 | 10 | 1.36% | 2.83% | 4.68% | Q3 2018 | Q4 2020 | 10 |
JANX | JANUX THERAPEUTICS INC | 10 | 10 | 1.82% | 2.56% | 3.47% | Q2 2021 | Q3 2023 | 10 |
DAWN | DAY ONE BIOPHARMACEUTI... | 10 | 10 | 1.31% | 2.15% | 3.36% | Q2 2021 | Q3 2023 | 10 |
CRNX | CRINETICS PHARMACEUTIC... | 10 | 10 | 0.11% | 1.58% | 3.27% | Q3 2018 | Q4 2020 | 10 |
KNTE | KINNATE BIOPHARMA INC | 10 | 10 | 0.53% | 1.20% | 2.00% | Q4 2020 | Q1 2023 | 10 |
GHRS | GH RESEARCH PLC | 10 | 10 | 0.92% | 1.19% | 1.93% | Q2 2021 | Q3 2023 | 10 |
RCKT | ROCKET PHARMACEUTICALS... | 10 | 10 | 0.44% | 0.98% | 1.64% | Q4 2020 | Q1 2023 | 10 |
TENX | TENAX THERAPEUTICS INC | 10 | 10 | 0.57% | 0.87% | 1.15% | Q3 2014 | Q4 2016 | 10 |
COGT | COGENT COMMUNICATIONS ... | 5 | 5 | 0.12% | 0.75% | 1.46% | Q4 2020 | Q3 2023 | 10 |
DSGN | DESIGN THERAPEUTICS INC | 10 | 10 | 0.35% | 0.69% | 0.99% | Q1 2021 | Q2 2023 | 10 |
HOWL | WEREWOLF THERAPEUTICS INC | 10 | 10 | 0.18% | 0.56% | 1.20% | Q2 2021 | Q3 2023 | 10 |
HSAQ | HEALTH SCIENCES ACQ CO... | 10 | 10 | 0.09% | 0.12% | 0.17% | Q3 2020 | Q4 2022 | 10 |
AVXS | AVEXIS INC | 9 | 9 | 4.74% | 10.09% | 15.16% | Q1 2016 | Q1 2018 | 9 |
SGMO | SANGAMO BIOSCIENCES INC | 9 | 9 | 3.11% | 6.87% | 9.85% | Q2 2013 | Q2 2015 | 9 |
LEGN | LEGEND BIOTECH CORP-ADR | 5 | 1 | 0.64% | 3.18% | 8.28% | Q2 2020 | Q3 2023 | 9 |
CYTEK BIOSCIENCES INC | 9 | 9 | 0.74% | 2.79% | 4.20% | Q3 2021 | Q3 2023 | 9 | |
TVTX | TRAVERE THERAPEUTICS INC | 9 | 9 | 1.32% | 2.26% | 3.18% | Q4 2020 | Q4 2022 | 9 |
BLUE | BLUEBIRD BIO INC | 9 | 9 | 0.76% | 2.17% | 4.99% | Q3 2013 | Q3 2015 | 9 |
PHAT | PHATHOM PHARMACEUTICAL... | 9 | 9 | 1.08% | 2.13% | 3.44% | Q4 2019 | Q4 2021 | 9 |
TYRA BIOSCIENCES INC | 9 | 9 | 1.12% | 1.78% | 2.63% | Q3 2021 | Q3 2023 | 9 | |
ELIEM THERAPEUTICS INC | 9 | 9 | 0.68% | 1.48% | 3.28% | Q3 2021 | Q3 2023 | 9 | |
ABOS | ACUMEN PHARMACEUTICALS... | 9 | 9 | 0.83% | 1.27% | 2.09% | Q3 2021 | Q3 2023 | 9 |
ICOSAVAX INC | 9 | 9 | 0.40% | 1.19% | 2.37% | Q3 2021 | Q3 2023 | 9 | |
CLDX | CELLDEX THERAPEUTICS I... | 7 | 2 | 0.10% | 1.15% | 1.88% | Q2 2020 | Q1 2023 | 9 |
RNA | AVIDITY BIOSCIENCES INC | 9 | 9 | 0.14% | 1.07% | 2.46% | Q3 2021 | Q3 2023 | 9 |
RXSIGHT INC | 9 | 9 | 0.54% | 1.02% | 1.68% | Q3 2021 | Q3 2023 | 9 | |
IGMS | IGM BIOSCIENCES INC | 7 | 2 | 0.15% | 0.97% | 1.74% | Q3 2019 | Q3 2023 | 9 |
PMVP | PMV PHARMACEUTICALS INC | 9 | 9 | 0.43% | 0.85% | 1.47% | Q3 2020 | Q3 2022 | 9 |
SBTX | SILVERBACK THERAPEUTIC... | 5 | 4 | 0.20% | 0.63% | 1.15% | Q4 2020 | Q3 2023 | 9 |
TENAYA THERAPEUTICS INC | 9 | 9 | 0.10% | 0.60% | 1.19% | Q3 2021 | Q3 2023 | 9 | |
MIST | MILESTONE PHARMACEUTIC... | 9 | 9 | 0.18% | 0.28% | 0.44% | Q3 2020 | Q3 2022 | 9 |
LRMR | LARIMAR THERAPEUTICS INC | 9 | 9 | 0.05% | 0.28% | 0.45% | Q2 2020 | Q2 2022 | 9 |
NVAX | NOVAVAX INC | 8 | 8 | 1.11% | 5.67% | 8.72% | Q2 2020 | Q1 2022 | 8 |
DICE THERAPEUTICS INC | 8 | 8 | 2.16% | 3.45% | 6.89% | Q3 2021 | Q2 2023 | 8 | |
ACAD | ACADIA PHARMACEUTICALS... | 4 | 4 | 0.09% | 3.22% | 15.72% | Q2 2013 | Q2 2015 | 8 |
AQXP | AQUINOX PHARMACEUTICAL... | 8 | 8 | 1.55% | 2.92% | 5.13% | Q3 2015 | Q2 2017 | 8 |
XNCR | XENCOR INC | 8 | 8 | 1.19% | 2.13% | 3.27% | Q4 2013 | Q3 2015 | 8 |
ALEC | ALECTOR INC | 8 | 8 | 0.34% | 1.17% | 3.15% | Q1 2019 | Q4 2020 | 8 |
RLMD | RELMADA THERAPEUTICS INC | 4 | 4 | 0.54% | 1.03% | 1.58% | Q4 2019 | Q3 2022 | 8 |
DYN | DYNE THERAPEUTICS INC | 8 | 8 | 0.51% | 0.72% | 1.04% | Q3 2020 | Q2 2022 | 8 |
AKUS | AKOUOS INC | 8 | 8 | 0.24% | 0.56% | 1.00% | Q2 2020 | Q1 2022 | 8 |
VRDN | VIRIDIAN THERAPEUTICS INC | 5 | 3 | 0.00% | 0.47% | 1.16% | Q1 2021 | Q3 2023 | 8 |
ACHL | ACHILLES THERAPEUTICS PLC | 8 | 8 | 0.03% | 0.38% | 0.79% | Q1 2021 | Q4 2022 | 8 |
BLSA | BCLS ACQUISITION CORP | 8 | 8 | 0.17% | 0.23% | 0.33% | Q4 2020 | Q3 2022 | 8 |
XFOR | X4 PHARMACEUTICALS INC | 8 | 8 | 0.05% | 0.20% | 0.69% | Q2 2019 | Q1 2021 | 8 |
FLACU | FRAZIER LIFESCIENCES A... | 8 | 8 | 0.14% | 0.18% | 0.26% | Q4 2020 | Q3 2022 | 8 |
FVAM | 5 01 ACQUISITION CORP | 8 | 8 | 0.10% | 0.14% | 0.20% | Q4 2020 | Q3 2022 | 8 |
ENTX | ENTERA BIO LTD | 8 | 8 | 0.00% | 0.10% | 0.23% | Q2 2021 | Q1 2023 | 8 |
ACAD | ACADIA PHARMACEUTICALS... | 7 | 7 | 3.41% | 11.76% | 15.36% | Q2 2013 | Q4 2014 | 7 |
ENTA | ENANTA PHARMACEUTICALS... | 3 | 1 | 0.99% | 2.42% | 6.70% | Q2 2013 | Q3 2022 | 7 |
MNTA | MOMENTA PHARMACEUTICAL... | 4 | 3 | 0.86% | 2.15% | 4.92% | Q2 2018 | Q2 2020 | 7 |
ACHN | ACHILLION PHARMACEUTIC... | 7 | 7 | 0.71% | 2.13% | 3.54% | Q2 2013 | Q4 2014 | 7 |
GTHX | G1 THERAPEUTICS INC | 5 | 2 | 0.11% | 1.63% | 5.37% | Q2 2017 | Q2 2019 | 7 |
TIL | INSTIL BIO INC | 7 | 7 | 0.79% | 1.27% | 1.84% | Q1 2021 | Q3 2022 | 7 |
AN2 THERAPEUTICS INC | 7 | 7 | 0.61% | 1.04% | 1.76% | Q1 2022 | Q3 2023 | 7 | |
EIGR | EIGER BIOPHARMACEUTICA... | 5 | 2 | 0.49% | 0.84% | 1.46% | Q1 2016 | Q1 2019 | 7 |
OLMA | OLEMA PHARMACEUTICALS INC | 7 | 7 | 0.02% | 0.68% | 1.44% | Q4 2020 | Q2 2022 | 7 |
PTCT | PTC THERAPEUTICS INC | 4 | 3 | 0.12% | 0.65% | 1.84% | Q3 2013 | Q2 2015 | 7 |
RLAY | RELAY THERAPEUTICS INC | 4 | 3 | 0.24% | 0.45% | 0.78% | Q3 2020 | Q3 2022 | 7 |
OCRX | OCERA THERAPEUTICS INC | 7 | 7 | 0.19% | 0.38% | 1.00% | Q3 2013 | Q1 2015 | 7 |
IMRA | IMARA INC | 6 | 1 | 0.03% | 0.24% | 0.74% | Q1 2020 | Q4 2022 | 7 |
CVRX | CVRX INC | 7 | 7 | 0.04% | 0.07% | 0.12% | Q2 2021 | Q4 2022 | 7 |
AXGT | AXOVANT SCIENCES LTD | 6 | 6 | 7.22% | 8.65% | 10.25% | Q2 2015 | Q3 2016 | 6 |
RGLS | REGULUS THERAPEUTICS INC | 6 | 6 | 0.93% | 4.35% | 8.18% | Q4 2014 | Q1 2016 | 6 |
IFRX | INFLARX NV | 6 | 6 | 3.58% | 4.22% | 5.04% | Q4 2017 | Q1 2019 | 6 |
CHRS | COHERUS BIOSCIENCES INC | 6 | 6 | 2.73% | 3.59% | 4.72% | Q4 2014 | Q1 2016 | 6 |
SNSS | SUNESIS PHARMACEUTICAL... | 6 | 6 | 2.31% | 3.01% | 4.11% | Q2 2013 | Q3 2014 | 6 |
AIMT | AIMMUNE THERAPEUTICS INC | 6 | 6 | 1.44% | 2.08% | 2.87% | Q3 2015 | Q4 2016 | 6 |
DVAX | DYNAVAX TECHNOLOGIES CORP | 6 | 6 | 0.74% | 2.06% | 4.08% | Q2 2013 | Q3 2014 | 6 |
BLU | BELLUS HEALTH INC NEW | 6 | 6 | 1.45% | 2.04% | 2.56% | Q4 2021 | Q1 2023 | 6 |
PEPGEN INC | 6 | 6 | 0.81% | 1.73% | 2.25% | Q2 2022 | Q3 2023 | 6 | |
DSCI | DERMA SCIENCES INC | 4 | 2 | 0.03% | 1.69% | 3.53% | Q2 2013 | Q1 2016 | 6 |
ADVM | ADVERUM BIOTECHNOLOGIE... | 5 | 1 | 0.06% | 1.68% | 3.17% | Q1 2020 | Q2 2022 | 6 |
NLNK | NEWLINK GENETICS CORP | 4 | 2 | 0.08% | 1.49% | 4.81% | Q2 2013 | Q2 2015 | 6 |
INBX | INHIBRX INC | 4 | 2 | 0.70% | 1.48% | 1.93% | Q3 2020 | Q3 2023 | 6 |
KERX | KERYX BIOPHARMACEUTICA... | 4 | 2 | 0.06% | 1.41% | 5.61% | Q2 2013 | Q2 2015 | 6 |
ADHD | ALCOBRA LTD | 6 | 6 | 0.52% | 1.39% | 1.89% | Q2 2015 | Q3 2016 | 6 |
PRVL | PREVAIL THERAPEUTICS INC | 6 | 6 | 0.36% | 1.39% | 2.46% | Q2 2019 | Q3 2020 | 6 |
NTRA | NATERA INC | 4 | 2 | 0.84% | 1.12% | 1.31% | Q3 2015 | Q2 2022 | 6 |
TRILLIUM THERAPEUTICS INC | 6 | 6 | 0.81% | 1.03% | 1.60% | Q1 2020 | Q2 2021 | 6 | |
NSTG | NANOSTRING TECHNOLOGIE... | 6 | 6 | 0.02% | 0.54% | 1.25% | Q2 2022 | Q3 2023 | 6 |
BOLT | BOLT BIOTHERAPEUTICS INC | 4 | 2 | 0.02% | 0.41% | 1.18% | Q1 2021 | Q3 2022 | 6 |
AKTX | AKARI THERAPEUTICS PLC | 6 | 6 | 0.10% | 0.38% | 0.91% | Q3 2015 | Q4 2016 | 6 |
DA32 LIFE SCNCE TEC AC... | 6 | 6 | 0.20% | 0.30% | 0.39% | Q3 2021 | Q4 2022 | 6 | |
ABIO | ARCA BIOPHARMA INC | 6 | 6 | 0.09% | 0.29% | 0.58% | Q3 2015 | Q4 2016 | 6 |
OCUL | OCULAR THERAPEUTIX INC | 6 | 6 | 0.10% | 0.25% | 0.44% | Q2 2020 | Q3 2021 | 6 |
ARYA SCIENCES ACQUISIT... | 6 | 6 | 0.14% | 0.20% | 0.26% | Q3 2021 | Q4 2022 | 6 | |
THOR | SYNTHORX INC | 5 | 5 | 7.05% | 11.09% | 20.61% | Q4 2018 | Q4 2019 | 5 |
SAGE | SAGE THERAPEUTICS INC | 4 | 1 | 2.63% | 3.90% | 6.27% | Q4 2017 | Q1 2019 | 5 |
OPHT | OPHTHOTECH CORP | 5 | 5 | 1.50% | 3.39% | 6.03% | Q4 2013 | Q4 2014 | 5 |
IMMU | IMMUNOMEDICS INC | 3 | 1 | 0.37% | 2.60% | 4.79% | Q2 2014 | Q4 2018 | 5 |
INSM | INSMED INC | 2 | 1 | 0.04% | 2.17% | 4.86% | Q2 2013 | Q2 2020 | 5 |
RTRX | RETROPHIN INC | 5 | 5 | 1.56% | 1.98% | 2.75% | Q3 2019 | Q3 2020 | 5 |
AVEO | AVEO PHARMACEUTICALS INC | 5 | 5 | 0.74% | 1.79% | 3.74% | Q2 2017 | Q2 2018 | 5 |
ARWR | ARROWHEAD RESH CORP | 5 | 5 | 0.52% | 1.66% | 3.46% | Q2 2013 | Q2 2014 | 5 |
CDTX | CIDARA THERAPEUTICS INC | 5 | 5 | 0.59% | 1.65% | 2.16% | Q2 2015 | Q2 2016 | 5 |
SBBP | STRONGBRIDGE BIOPHARMA... | 5 | 5 | 0.78% | 1.44% | 2.02% | Q4 2015 | Q4 2016 | 5 |
AKBA | AKEBIA THERAPEUTICS INC | 4 | 1 | 0.66% | 1.20% | 1.68% | Q2 2014 | Q2 2017 | 5 |
DMTX | DIMENSION THERAPEUTICS... | 5 | 5 | 0.57% | 1.18% | 1.55% | Q4 2015 | Q4 2016 | 5 |
MCRB | SERES THERAPEUTICS INC | 2 | 1 | 0.03% | 1.14% | 2.46% | Q2 2015 | Q2 2021 | 5 |
STOK | STOKE THERAPEUTICS INC | 5 | 5 | 0.52% | 1.10% | 1.75% | Q2 2019 | Q2 2020 | 5 |
MRTX | MIRATI THERAPEUTICS INC | 3 | 2 | 0.87% | 1.07% | 1.32% | Q3 2013 | Q1 2022 | 5 |
FULC | FULCRUM THERAPEUTICS INC | 5 | 5 | 0.72% | 1.02% | 1.40% | Q3 2022 | Q3 2023 | 5 |
AGRX | AGILE THERAPEUTICS INC | 3 | 2 | 0.61% | 0.99% | 1.34% | Q1 2015 | Q2 2016 | 5 |
IOVA | IOVANCE BIOTHERAPEUTIC... | 5 | 5 | 0.67% | 0.99% | 1.40% | Q1 2018 | Q1 2019 | 5 |
ALPN | ALPINE IMMUNE SCIENCES... | 5 | 5 | 0.66% | 0.82% | 1.06% | Q3 2022 | Q3 2023 | 5 |
EWTX | EDGEWISE THERAPEUTICS INC | 5 | 5 | 0.55% | 0.81% | 1.28% | Q1 2021 | Q1 2022 | 5 |
BGNE | BEIGENE LTD | 5 | 5 | 0.54% | 0.80% | 1.08% | Q1 2016 | Q1 2017 | 5 |
CCCC | C4 THERAPEUTICS INC | 5 | 5 | 0.64% | 0.78% | 0.85% | Q4 2020 | Q4 2021 | 5 |
VICL | VICAL INC | 5 | 5 | 0.14% | 0.48% | 0.72% | Q3 2014 | Q3 2015 | 5 |
EARS | AURIS MED HLDG AG | 5 | 5 | 0.24% | 0.45% | 0.64% | Q3 2014 | Q3 2015 | 5 |
IPSC | CENTURY THERAPEUTICS INC | 5 | 5 | 0.17% | 0.28% | 0.43% | Q2 2021 | Q2 2022 | 5 |
SYBX | SYNLOGIC INC | 5 | 5 | 0.09% | 0.24% | 0.35% | Q3 2021 | Q3 2022 | 5 |
AGIO | AGIOS PHARMACEUTICALS INC | 4 | 1 | 0.11% | 0.16% | 0.21% | Q3 2013 | Q2 2015 | 5 |
IO BIOTECH INC | 5 | 5 | 0.05% | 0.16% | 0.23% | Q4 2021 | Q4 2022 | 5 | |
AADI BIOSCIENCES INC | 4 | 1 | 0.10% | 0.14% | 0.18% | Q3 2021 | Q1 2023 | 5 | |
WGBS | WAFERGEN BIO-SYSTEMS INC | 5 | 5 | 0.04% | 0.14% | 0.29% | Q3 2014 | Q3 2015 | 5 |
PHAS | PHASEBIO PHARMACEUTICA... | 5 | 5 | 0.08% | 0.13% | 0.17% | Q1 2021 | Q1 2022 | 5 |
EPIX | ESSA PHARMA INC | 5 | 5 | 0.06% | 0.13% | 0.20% | Q3 2019 | Q3 2020 | 5 |
CGEM | CULLINAN ONCOLOGY INC COM | 5 | 5 | 0.08% | 0.13% | 0.22% | Q1 2021 | Q1 2022 | 5 |
BMEA | BIOMEA FUSION INC | 5 | 5 | 0.05% | 0.10% | 0.16% | Q2 2021 | Q2 2022 | 5 |
BHVN | BIOHAVEN PHARMACTL HLD... | 4 | 4 | 0.72% | 4.75% | 7.02% | Q2 2017 | Q1 2018 | 4 |
NKTR | NEKTAR THERAPEUTICS | 3 | 1 | 0.22% | 4.66% | 6.49% | Q1 2016 | Q3 2023 | 4 |
ECYT | ENDOCYTE INC | 4 | 4 | 1.20% | 3.71% | 5.88% | Q4 2017 | Q3 2018 | 4 |
PRTA | PROTHENA CORP PLC | 4 | 4 | 0.85% | 3.42% | 5.07% | Q2 2013 | Q1 2014 | 4 |
AVIR | ATEA PHARMACEUTICALS INC | 4 | 4 | 1.85% | 3.16% | 5.00% | Q4 2020 | Q3 2021 | 4 |
COLL | COLLEGIUM PHARMACEUTIC... | 4 | 4 | 1.13% | 2.79% | 4.93% | Q2 2015 | Q1 2016 | 4 |
DVAX | DYNAVAX TECHNOLOGIES CORP | 2 | 2 | 0.41% | 2.13% | 5.79% | Q1 2015 | Q4 2019 | 4 |
VSAR | VERSARTIS INC | 4 | 4 | 0.42% | 2.02% | 5.06% | Q2 2014 | Q1 2015 | 4 |
BPMC | BLUEPRINT MEDICINES CORP | 4 | 4 | 0.13% | 1.86% | 2.69% | Q2 2015 | Q1 2016 | 4 |
ACOR | ACORDA THERAPEUTICS INC | 3 | 1 | 1.26% | 1.73% | 2.04% | Q1 2016 | Q3 2017 | 4 |
BLCM | BELLICUM PHARMACEUTICA... | 4 | 4 | 0.66% | 1.56% | 2.36% | Q4 2014 | Q3 2015 | 4 |
OMER | OMEROS CORP | 2 | 2 | 1.07% | 1.51% | 1.97% | Q2 2013 | Q2 2015 | 4 |
NEWAMSTERDAM PHARMA CO NV | 4 | 4 | 0.88% | 1.44% | 2.02% | Q4 2022 | Q3 2023 | 4 | |
ADAP | ADAPTIMMUNE THERAPEUTI... | 4 | 4 | 0.19% | 1.37% | 2.55% | Q1 2020 | Q4 2020 | 4 |
BOLD | AUDENTES THERAPEUTICS INC | 3 | 1 | 1.11% | 1.36% | 1.64% | Q3 2016 | Q4 2019 | 4 |
APLS | APELLIS PHARMACEUTICAL... | 4 | 4 | 0.86% | 1.32% | 1.63% | Q4 2017 | Q3 2018 | 4 |
PNT | POINT BIOPHARMA GLOBAL... | 4 | 4 | 0.89% | 1.26% | 1.64% | Q3 2021 | Q2 2022 | 4 |
VTAE | VITAE PHARMACEUTICALS INC | 4 | 4 | 0.51% | 1.19% | 2.35% | Q3 2015 | Q2 2016 | 4 |
ACRIVON THERAPEUTICS INC | 4 | 4 | 0.90% | 1.15% | 1.38% | Q4 2022 | Q3 2023 | 4 | |
TSRO | TESARO INC | 2 | 2 | 0.13% | 1.01% | 2.30% | Q4 2013 | Q2 2015 | 4 |
DNAI | PRONAI THERAPEUTICS INC | 4 | 4 | 0.01% | 0.80% | 1.78% | Q3 2015 | Q2 2016 | 4 |
NVLS | NIVALIS THERAPEUTICS INC | 4 | 4 | 0.33% | 0.77% | 1.15% | Q2 2015 | Q1 2016 | 4 |
SCYX | SCYNEXIS INC | 4 | 4 | 0.65% | 0.74% | 0.90% | Q2 2014 | Q1 2015 | 4 |
CYT | CYTEIR THERAPEUTICS INC | 4 | 4 | 0.28% | 0.72% | 1.12% | Q2 2021 | Q1 2022 | 4 |
ARQT | ARCUTIS BIOTHERAPEUTIC... | 4 | 4 | 0.46% | 0.72% | 1.10% | Q1 2020 | Q4 2020 | 4 |
GRPH | GRAPHITE BIO INC | 4 | 4 | 0.30% | 0.71% | 1.33% | Q2 2021 | Q1 2022 | 4 |
CNTA | CENTESSA PHARMACEUTICA... | 4 | 4 | 0.46% | 0.67% | 0.83% | Q2 2021 | Q1 2022 | 4 |
INZY | INOZYME PHARMA INC | 4 | 4 | 0.55% | 0.67% | 0.96% | Q3 2020 | Q2 2021 | 4 |
PARDES BIOSCIENCES INC | 4 | 4 | 0.24% | 0.66% | 0.97% | Q4 2021 | Q3 2022 | 4 | |
ZYNE | ZYNERBA PHARMACEUTICAL... | 4 | 4 | 0.24% | 0.61% | 1.08% | Q3 2015 | Q2 2016 | 4 |
HILLEVAX INC | 4 | 4 | 0.51% | 0.60% | 0.66% | Q2 2022 | Q1 2023 | 4 | |
STRO | SUTRO BIOPHARMA INC | 4 | 4 | 0.29% | 0.51% | 0.73% | Q2 2020 | Q1 2021 | 4 |
VERV | VERVE THERAPEUTICS INC | 4 | 4 | 0.16% | 0.45% | 0.85% | Q2 2021 | Q1 2022 | 4 |
CELC | CELCUITY INC | 4 | 4 | 0.25% | 0.32% | 0.40% | Q4 2022 | Q3 2023 | 4 |
SOLID BIOSCIENCES INC | 4 | 4 | 0.17% | 0.31% | 0.37% | Q4 2022 | Q3 2023 | 4 | |
SNDX | SYNDAX PHARMACEUTICALS... | 4 | 4 | 0.28% | 0.31% | 0.34% | Q2 2020 | Q1 2021 | 4 |
TTOO | T2 BIOSYSTEMS INC | 4 | 4 | 0.21% | 0.25% | 0.30% | Q3 2014 | Q2 2015 | 4 |
GRTX | GALERA THERAPEUTICS INC | 4 | 4 | 0.12% | 0.24% | 0.42% | Q4 2019 | Q3 2020 | 4 |
BCTG | BCTG ACQUISITION CORP | 4 | 4 | 0.20% | 0.22% | 0.24% | Q3 2020 | Q2 2021 | 4 |
RPTX | REPARE THERAPEUTICS INC | 4 | 4 | 0.19% | 0.22% | 0.25% | Q2 2020 | Q1 2021 | 4 |
OTIC | OTONOMY INC | 4 | 4 | 0.04% | 0.21% | 0.31% | Q3 2021 | Q2 2022 | 4 |
IKNA | IKENA ONCOLOGY INC | 4 | 4 | 0.13% | 0.20% | 0.32% | Q1 2021 | Q4 2021 | 4 |
PYXIS ONCOLOGY INC | 4 | 4 | 0.03% | 0.18% | 0.44% | Q4 2021 | Q3 2022 | 4 | |
MACK | MERRIMACK PHARMACEUTIC... | 4 | 4 | 0.12% | 0.14% | 0.14% | Q3 2014 | Q2 2015 | 4 |
PASG | PASSAGE BIO INC | 4 | 4 | 0.08% | 0.13% | 0.17% | Q1 2020 | Q4 2020 | 4 |
ASTRIA THERAPEUTICS INC | 4 | 4 | 0.06% | 0.13% | 0.18% | Q3 2021 | Q2 2022 | 4 | |
ALKS | ALKERMES PLC | 4 | 4 | 0.10% | 0.11% | 0.12% | Q3 2014 | Q2 2015 | 4 |
REGN | REGENERON PHARMACEUTICALS | 4 | 4 | 0.10% | 0.11% | 0.13% | Q3 2014 | Q2 2015 | 4 |
HLXA | HELIX ACQUISITION CORP | 4 | 4 | 0.10% | 0.11% | 0.12% | Q4 2020 | Q3 2021 | 4 |
CELG | CELGENE CORP | 4 | 4 | 0.10% | 0.10% | 0.10% | Q3 2014 | Q2 2015 | 4 |
AMGN | AMGEN INC | 4 | 4 | 0.09% | 0.10% | 0.10% | Q3 2014 | Q2 2015 | 4 |
SYRS | SYROS PHARMACEUTICALS INC | 4 | 4 | 0.05% | 0.07% | 0.10% | Q1 2021 | Q4 2021 | 4 |
PBYI | PUMA BIOTECHNOLOGY INC | 4 | 4 | 0.04% | 0.06% | 0.09% | Q3 2014 | Q2 2015 | 4 |
NEWAMSTERDAM PHARMA CO... | 4 | 4 | 0.01% | 0.01% | 0.01% | Q4 2022 | Q3 2023 | 4 | |
RXDX | IGNYTA INC | 3 | 3 | 1.08% | 3.48% | 4.77% | Q1 2017 | Q3 2017 | 3 |
ZSPH | ZS PHARMA INC | 3 | 3 | 2.36% | 2.50% | 2.62% | Q3 2014 | Q1 2015 | 3 |
ZFGN | ZAFGEN INC | 3 | 3 | 1.70% | 2.34% | 2.88% | Q3 2014 | Q1 2015 | 3 |
CVAC | CUREVAC NV | 3 | 3 | 1.43% | 1.92% | 2.41% | Q1 2023 | Q3 2023 | 3 |
FOMX | FOAMIX PHARMACEUTICALS... | 3 | 3 | 1.10% | 1.90% | 2.86% | Q3 2016 | Q1 2017 | 3 |
JUNO | JUNO THERAPEUTICS INC | 3 | 3 | 1.50% | 1.59% | 1.69% | Q4 2014 | Q2 2015 | 3 |
PTGX | PROTAGONIST THERAPEUTI... | 3 | 3 | 1.00% | 1.57% | 2.07% | Q3 2016 | Q1 2017 | 3 |
KROS | KEROS THERAPEUTICS INC | 3 | 3 | 1.32% | 1.51% | 1.85% | Q2 2020 | Q4 2020 | 3 |
DTIL | PRECISION BIOSCIENCES INC | 3 | 3 | 0.92% | 1.22% | 1.43% | Q1 2019 | Q3 2019 | 3 |
TRVN | TREVENA INC | 3 | 3 | 0.33% | 1.03% | 1.91% | Q4 2014 | Q2 2015 | 3 |
CRIS | CURIS INC | 3 | 3 | 0.88% | 1.01% | 1.22% | Q4 2020 | Q2 2021 | 3 |
MDCO | MEDICINES CO | 2 | 1 | 0.38% | 0.96% | 2.03% | Q2 2015 | Q1 2017 | 3 |
MINERALYS THERAPEUTICS... | 3 | 3 | 0.60% | 0.92% | 1.13% | Q1 2023 | Q3 2023 | 3 | |
SPRO | SPERO THERAPEUTICS INC | 3 | 3 | 0.71% | 0.91% | 1.20% | Q4 2017 | Q2 2018 | 3 |
ENZ | ENZO BIOCHEM INC | 3 | 3 | 0.77% | 0.86% | 0.92% | Q2 2013 | Q4 2013 | 3 |
ENLIVEN THERAPEUTICS INC | 3 | 3 | 0.57% | 0.81% | 1.05% | Q1 2023 | Q3 2023 | 3 | |
PSDV | PSIVIDA CORP | 3 | 3 | 0.55% | 0.81% | 1.12% | Q4 2013 | Q2 2014 | 3 |
VERA | VERA THERAPEUTICS INC | 3 | 3 | 0.57% | 0.77% | 1.01% | Q1 2022 | Q3 2022 | 3 |
PLRX | PLIANT THERAPEUTICS INC | 3 | 3 | 0.60% | 0.76% | 1.06% | Q1 2023 | Q3 2023 | 3 |
VSTM | VERASTEM INC | 3 | 3 | 0.18% | 0.68% | 1.55% | Q1 2020 | Q3 2020 | 3 |
AUPH | AURINIA PHARMACEUTICAL... | 3 | 3 | 0.35% | 0.66% | 0.97% | Q4 2014 | Q2 2015 | 3 |
CERE | CEREVEL THERAPEUTICS H... | 3 | 3 | 0.46% | 0.62% | 0.90% | Q4 2020 | Q2 2021 | 3 |
NEURODERM LTD | 3 | 3 | 0.24% | 0.59% | 1.26% | Q3 2015 | Q1 2016 | 3 | |
LIANBIO | 3 | 3 | 0.27% | 0.57% | 0.83% | Q4 2021 | Q2 2022 | 3 | |
KRYS | KRYSTAL BIOTECH INC | 3 | 3 | 0.38% | 0.54% | 0.63% | Q3 2017 | Q1 2018 | 3 |
THIRD HARMONIC BIO INC | 2 | 1 | 0.05% | 0.52% | 1.41% | Q3 2022 | Q3 2023 | 3 | |
NBIX | NEUROCRINE BIOSCIENCES... | 2 | 1 | 0.10% | 0.52% | 1.35% | Q1 2014 | Q2 2015 | 3 |
TANGO THERAPEUTICS INC | 3 | 3 | 0.37% | 0.40% | 0.43% | Q3 2021 | Q1 2022 | 3 | |
AGTC | APPLIED GENETIC TECHNO... | 3 | 3 | 0.23% | 0.38% | 0.48% | Q3 2015 | Q1 2016 | 3 |
DYAX | DYAX CORP | 3 | 3 | 0.32% | 0.37% | 0.44% | Q3 2013 | Q1 2014 | 3 |
PTLA | PORTOLA PHARMACEUTICAL... | 3 | 3 | 0.10% | 0.36% | 0.69% | Q3 2019 | Q1 2020 | 3 |
EPZM | EPIZYME INC | 2 | 1 | 0.04% | 0.34% | 0.56% | Q2 2013 | Q3 2015 | 3 |
CTMX | CYTOMX THERAPEUTICS INC | 3 | 3 | 0.25% | 0.34% | 0.41% | Q1 2021 | Q3 2021 | 3 |
XILIO THERAPEUTICS INC | 3 | 3 | 0.13% | 0.33% | 0.56% | Q4 2021 | Q2 2022 | 3 | |
ALIM | ALIMERA SCIENCES INC | 3 | 3 | 0.16% | 0.31% | 0.40% | Q1 2014 | Q3 2014 | 3 |
NAUT | NAUTILUS BIOTECHNOLOGY... | 3 | 3 | 0.21% | 0.28% | 0.40% | Q2 2021 | Q4 2021 | 3 |
BOTA | BIOTA PHARMACEUTIALS INC | 3 | 3 | 0.17% | 0.27% | 0.33% | Q4 2014 | Q2 2015 | 3 |
GLYC | GLYCOMIMETICS INC | 3 | 3 | 0.20% | 0.26% | 0.32% | Q1 2018 | Q3 2018 | 3 |
ORIC | ORIC PHARMACEUTICALS INC | 3 | 3 | 0.17% | 0.22% | 0.28% | Q4 2020 | Q2 2021 | 3 |
AGLE | AEGLEA BIOTHERAPEUTICS... | 2 | 1 | 0.00% | 0.19% | 0.35% | Q2 2016 | Q3 2022 | 3 |
ARYA | ARYA SCIENCES ACQUISIT... | 3 | 3 | 0.15% | 0.18% | 0.20% | Q3 2020 | Q1 2021 | 3 |
LYRA | LYRA THERAPEUTICS INC | 3 | 3 | 0.13% | 0.16% | 0.18% | Q2 2020 | Q4 2020 | 3 |
FSII | FS DEVELOPMENT CORP II | 3 | 3 | 0.14% | 0.15% | 0.16% | Q1 2021 | Q3 2021 | 3 |
CUE HEALTH INC | 3 | 3 | 0.11% | 0.14% | 0.18% | Q3 2021 | Q1 2022 | 3 | |
ATHA | ATHIRA PHARMA INC | 3 | 3 | 0.12% | 0.13% | 0.15% | Q2 2022 | Q4 2022 | 3 |
RGEN | REPLIGEN CORP | 3 | 3 | 0.10% | 0.11% | 0.14% | Q3 2014 | Q1 2015 | 3 |
TSCAN THERAPEUTICS INC | 3 | 3 | 0.06% | 0.10% | 0.14% | Q3 2021 | Q1 2022 | 3 | |
FUSN | FUSION PHARMACEUTICALS... | 3 | 3 | 0.04% | 0.05% | 0.06% | Q3 2022 | Q1 2023 | 3 |
CEREW | CEREVEL THERAPEUTICS H... | 3 | 3 | 0.02% | 0.03% | 0.05% | Q4 2020 | Q2 2021 | 3 |
APHB | AMPLIPHI BIOSCIENCES CORP | 3 | 3 | 0.02% | 0.03% | 0.04% | Q3 2015 | Q1 2016 | 3 |
OVID | OVID THERAPEUTICS INC | 3 | 3 | 0.01% | 0.03% | 0.04% | Q2 2020 | Q4 2020 | 3 |
ESPR | ESPERION THERAPEUTICS INC | 2 | 2 | 3.05% | 3.47% | 3.88% | Q1 2017 | Q2 2017 | 2 |
XOMA | XOMA CORP DEL | 2 | 2 | 3.22% | 3.23% | 3.24% | Q2 2013 | Q3 2013 | 2 |
HPTX | HYPERION THERAPEUTICS INC | 2 | 2 | 2.46% | 2.55% | 2.63% | Q2 2013 | Q3 2013 | 2 |
GBT | GLOBAL BLOOD THERAPEUT... | 2 | 2 | 1.46% | 2.12% | 2.77% | Q3 2015 | Q4 2015 | 2 |
ARNA | ARENA PHARMACEUTICAL S... | 2 | 2 | 1.64% | 2.00% | 2.36% | Q4 2015 | Q1 2016 | 2 |
RPRX | REPROS THERAPEUTICS INC | 2 | 2 | 1.83% | 1.98% | 2.13% | Q1 2014 | Q2 2014 | 2 |
KDMN | KADMON HLDGS INC | 2 | 2 | 1.90% | 1.96% | 2.02% | Q3 2017 | Q4 2017 | 2 |
ADAGIO THERAPEUTICS INC | 2 | 2 | 0.64% | 1.88% | 3.13% | Q3 2021 | Q4 2021 | 2 | |
MRNA | MODERNA INC | 2 | 2 | 1.33% | 1.34% | 1.35% | Q4 2018 | Q1 2019 | 2 |
RMTI | ROCKWELL MED INC | 2 | 2 | 1.19% | 1.20% | 1.22% | Q3 2013 | Q4 2013 | 2 |
CLSD | CLEARSIDE BIOMEDICAL INC | 2 | 2 | 1.06% | 1.16% | 1.25% | Q1 2018 | Q2 2018 | 2 |
NLNK | NEWLINK GENETICS CORP | 2 | 2 | 0.98% | 1.13% | 1.28% | Q3 2013 | Q4 2013 | 2 |
SWAV | SHOCKWAVE MED INC | 2 | 2 | 0.72% | 1.12% | 1.52% | Q1 2019 | Q2 2019 | 2 |
FDMT | 4D MOLECULAR THERAPEUT... | 2 | 2 | 1.04% | 1.04% | 1.05% | Q2 2023 | Q3 2023 | 2 |
KERX | KERYX BIOPHARMACEUTICA... | 2 | 2 | 0.99% | 1.02% | 1.05% | Q2 2013 | Q3 2013 | 2 |
OGXI | ONCOGENEX PHARMACEUTIC... | 2 | 2 | 0.74% | 0.93% | 1.12% | Q2 2013 | Q3 2013 | 2 |
CMTA | CLEMENTIA PHARMACEUTIC... | 2 | 2 | 0.89% | 0.91% | 0.93% | Q3 2017 | Q4 2017 | 2 |
AKRO | AKERO THERAPEUTICS INC | 2 | 2 | 0.70% | 0.88% | 1.07% | Q3 2022 | Q4 2022 | 2 |
CRDF | CARDIFF ONCOLOGY INC | 2 | 2 | 0.83% | 0.84% | 0.85% | Q3 2020 | Q4 2020 | 2 |
CNST | CONSTELLATION PHARMCET... | 2 | 2 | 0.75% | 0.77% | 0.79% | Q4 2020 | Q1 2021 | 2 |
VXRT | VAXART INC | 2 | 2 | 0.22% | 0.77% | 1.32% | Q3 2020 | Q4 2020 | 2 |
SNSS | SUNESIS PHARMACEUTICAL... | 2 | 2 | 0.52% | 0.74% | 0.96% | Q4 2017 | Q1 2018 | 2 |
SCMP | SUCAMPO PHARMACEUTICAL... | 2 | 2 | 0.70% | 0.72% | 0.74% | Q1 2015 | Q2 2015 | 2 |
GH | GUARDANT HEALTH INC | 2 | 2 | 0.51% | 0.60% | 0.69% | Q1 2022 | Q2 2022 | 2 |
ARRY | ARRAY BIOPHARMA INC | 2 | 2 | 0.09% | 0.54% | 0.99% | Q1 2015 | Q2 2015 | 2 |
RMTI | ROCKWELL MED INC | 2 | 2 | 0.27% | 0.53% | 0.78% | Q4 2014 | Q1 2015 | 2 |
CNDO | CORONADO BIOSCIENCES INC | 2 | 2 | 0.31% | 0.52% | 0.73% | Q3 2013 | Q4 2013 | 2 |
PAND | PANDION THERAPEUTICS INC | 2 | 2 | 0.37% | 0.37% | 0.37% | Q3 2020 | Q4 2020 | 2 |
MEIP | MEI PHARMA INC | 2 | 2 | 0.33% | 0.35% | 0.38% | Q4 2013 | Q1 2014 | 2 |
ODT | ODONATE THERAPEUTICS INC | 2 | 2 | 0.31% | 0.35% | 0.39% | Q2 2019 | Q3 2019 | 2 |
KDNY | CHINOOK THERAPEUTICS INC | 2 | 2 | 0.29% | 0.32% | 0.36% | Q4 2021 | Q1 2022 | 2 |
CHMA | CHIASMA INC | 2 | 2 | 0.17% | 0.24% | 0.32% | Q3 2017 | Q4 2017 | 2 |
CMRX | CHIMERIX INC | 1 | 1 | 0.12% | 0.19% | 0.25% | Q3 2019 | Q3 2023 | 2 |
ARYD | ARYA SCIENCES ACQU COR... | 2 | 2 | 0.16% | 0.16% | 0.17% | Q1 2021 | Q2 2021 | 2 |
ARYBU | ARYA SCIENCES ACQUISIT... | 2 | 2 | 0.14% | 0.15% | 0.16% | Q2 2020 | Q3 2020 | 2 |
TALS | TALARIS THERAPEUTICS INC | 2 | 2 | 0.13% | 0.13% | 0.13% | Q2 2023 | Q3 2023 | 2 |
DBVT | DBV TECHNOLOGIES S A | 2 | 2 | 0.06% | 0.10% | 0.14% | Q3 2022 | Q4 2022 | 2 |
DRRX | DURECT CORP | 2 | 2 | 0.09% | 0.10% | 0.11% | Q2 2015 | Q3 2015 | 2 |
KYTH | KYTHERA BIOPHARMACEUTI... | 2 | 2 | 0.08% | 0.09% | 0.09% | Q3 2014 | Q4 2014 | 2 |
CLDN | CELLADON CORP | 2 | 2 | 0.08% | 0.08% | 0.09% | Q4 2014 | Q1 2015 | 2 |
CMPX | COMPASS THERAPEUTICS INC | 2 | 2 | 0.02% | 0.06% | 0.10% | Q4 2021 | Q1 2022 | 2 |
SELB | SELECTA BIOSCIENCES INC | 2 | 2 | 0.01% | 0.04% | 0.07% | Q1 2020 | Q2 2020 | 2 |
SNSE | SENSEI BIOTHERAPEUTICS | 2 | 2 | 0.02% | 0.03% | 0.04% | Q2 2022 | Q3 2022 | 2 |
SAVIENT PHARMACEUTICAL... | 2 | 2 | 0.02% | 0.02% | 0.03% | Q2 2013 | Q3 2013 | 2 | |
PRAN | PRANA BIOTECHNOLOGY LTD | 2 | 2 | 0.02% | 0.02% | 0.02% | Q1 2014 | Q2 2014 | 2 |
RPHM | RENEO PHARMACEUTICALS INC | 2 | 2 | 0.01% | 0.01% | 0.01% | Q2 2021 | Q3 2021 | 2 |
GILD | GILEAD SCIENCES INC | 1 | 1 | 12.20% | 12.20% | 12.20% | Q1 2014 | Q1 2014 | 1 |
AVNR | AVANIR PHARMACEUTICALS... | 1 | 1 | 7.59% | 7.59% | 7.59% | Q3 2014 | Q3 2014 | 1 |
TKMR | TEKMIRA PHARMACEUTICAL... | 1 | 1 | 4.71% | 4.71% | 4.71% | Q1 2015 | Q1 2015 | 1 |
RDUS | RADIUS HEALTH INC | 1 | 1 | 2.58% | 2.58% | 2.58% | Q2 2017 | Q2 2017 | 1 |
RCPT | RECEPTOS INC | 1 | 1 | 2.57% | 2.57% | 2.57% | Q2 2013 | Q2 2013 | 1 |
EXEL | EXELIXIS INC | 1 | 1 | 2.46% | 2.46% | 2.46% | Q1 2020 | Q1 2020 | 1 |
VERU | VERU INC | 1 | 1 | 2.38% | 2.38% | 2.38% | Q2 2022 | Q2 2022 | 1 |
FTSV | FORTY SEVEN INC | 1 | 1 | 2.31% | 2.31% | 2.31% | Q4 2019 | Q4 2019 | 1 |
FWP | FORWARD PHARMA A/S | 1 | 1 | 2.17% | 2.17% | 2.17% | Q4 2014 | Q4 2014 | 1 |
CBAY | CYMABAY THERAPEUTICS INC | 1 | 1 | 2.04% | 2.04% | 2.04% | Q3 2023 | Q3 2023 | 1 |
CPXX | CELATOR PHARMACEUTICAL... | 1 | 1 | 1.99% | 1.99% | 1.99% | Q1 2016 | Q1 2016 | 1 |
ITCI | INTRA CELLULAR THERAPI... | 1 | 1 | 1.81% | 1.81% | 1.81% | Q3 2015 | Q3 2015 | 1 |
LOXO | LOXO ONCOLOGY INC | 1 | 1 | 1.54% | 1.54% | 1.54% | Q1 2017 | Q1 2017 | 1 |
EVH | EVOLENT HEALTH INC - A | 1 | 1 | 1.47% | 1.47% | 1.47% | Q3 2023 | Q3 2023 | 1 |
AGEN | AGENUS INC | 1 | 1 | 1.39% | 1.39% | 1.39% | Q2 2015 | Q2 2015 | 1 |
GILD | GILEAD SCIENCES INC | 1 | 1 | 1.29% | 1.29% | 1.29% | Q1 2020 | Q1 2020 | 1 |
XLRN | ACCELERON PHARMA INC | 1 | 1 | 1.19% | 1.19% | 1.19% | Q3 2016 | Q3 2016 | 1 |
ARWR | ARROWHEAD PHARMACEUTIC... | 1 | 1 | 1.16% | 1.16% | 1.16% | Q3 2016 | Q3 2016 | 1 |
TSHA | TAYSHA GENE THERAPIES INC | 1 | 1 | 1.15% | 1.15% | 1.15% | Q3 2023 | Q3 2023 | 1 |
MYGN | MYRIAD GENETICS INC | 1 | 1 | 1.10% | 1.10% | 1.10% | Q3 2013 | Q3 2013 | 1 |
AMPE | AMPIO PHARMACEUTICALS INC | 1 | 1 | 1.04% | 1.04% | 1.04% | Q3 2013 | Q3 2013 | 1 |
CALA | CALITHERA BIOSCIENCES INC | 1 | 1 | 1.03% | 1.03% | 1.03% | Q1 2017 | Q1 2017 | 1 |
FPRX | FIVE PRIME THERAPEUTIC... | 1 | 1 | 1.02% | 1.02% | 1.02% | Q4 2020 | Q4 2020 | 1 |
CBIO | CATALYST BIOSCIENCES INC | 1 | 1 | 1.02% | 1.02% | 1.02% | Q1 2018 | Q1 2018 | 1 |
PGNX | PROGENICS PHARMACEUTIC... | 1 | 1 | 1.02% | 1.02% | 1.02% | Q3 2018 | Q3 2018 | 1 |
OREX | OREXIGEN THERAPEUTICS INC | 1 | 1 | 0.92% | 0.92% | 0.92% | Q1 2015 | Q1 2015 | 1 |
AQUINOX PHARMACEUTICAL... | 1 | 1 | 0.91% | 0.91% | 0.91% | Q3 2017 | Q3 2017 | 1 | |
KOD | KODIAK SCIENCES INC | 1 | 1 | 0.88% | 0.88% | 0.88% | Q3 2019 | Q3 2019 | 1 |
APOGEE THERAPEUTICS INC | 1 | 1 | 0.83% | 0.83% | 0.83% | Q3 2023 | Q3 2023 | 1 | |
ABEO | ABEONA THERAPEUTICS INC | 1 | 1 | 0.78% | 0.78% | 0.78% | Q4 2016 | Q4 2016 | 1 |
RARE | ULTRAGENYX PHARMACEUTI... | 1 | 1 | 0.78% | 0.78% | 0.78% | Q3 2015 | Q3 2015 | 1 |
ALNY | ALNYLAM PHARMACEUTICAL... | 1 | 1 | 0.73% | 0.73% | 0.73% | Q3 2015 | Q3 2015 | 1 |
ITMN | INTERMUNE INC | 1 | 1 | 0.72% | 0.72% | 0.72% | Q1 2014 | Q1 2014 | 1 |
PACB | PACIFIC BIOSCIENCES OF... | 1 | 1 | 0.72% | 0.72% | 0.72% | Q4 2020 | Q4 2020 | 1 |
SOLENO THERAPEUTICS INC | 1 | 1 | 0.72% | 0.72% | 0.72% | Q3 2023 | Q3 2023 | 1 | |
VKTX | VIKING THERAPEUTICS INC | 1 | 1 | 0.68% | 0.68% | 0.68% | Q1 2018 | Q1 2018 | 1 |
CGEN | COMPUGEN LTD | 1 | 1 | 0.68% | 0.68% | 0.68% | Q1 2020 | Q1 2020 | 1 |
ABIO | ARCA BIOPHARMA INC | 1 | 1 | 0.66% | 0.66% | 0.66% | Q2 2015 | Q2 2015 | 1 |
CTIC | CTI BIOPHARMA CORP | 1 | 1 | 0.63% | 0.63% | 0.63% | Q4 2014 | Q4 2014 | 1 |
ACET | ADICET BIO INC | 1 | 1 | 0.62% | 0.62% | 0.62% | Q3 2022 | Q3 2022 | 1 |
MDGL | MADRIGAL PHARMACEUTICA... | 1 | 1 | 0.59% | 0.59% | 0.59% | Q3 2023 | Q3 2023 | 1 |
NVCR | NOVOCURE LTD | 1 | 1 | 0.55% | 0.55% | 0.55% | Q1 2020 | Q1 2020 | 1 |
FLXN | FLEXION THERAPEUTICS INC | 1 | 1 | 0.53% | 0.53% | 0.53% | Q1 2014 | Q1 2014 | 1 |
AVDL | AVADEL PHARMACEUTICALS... | 1 | 1 | 0.49% | 0.49% | 0.49% | Q2 2020 | Q2 2020 | 1 |
IDRA | IDERA PHARMACEUTICALS INC | 1 | 1 | 0.48% | 0.48% | 0.48% | Q4 2016 | Q4 2016 | 1 |
URGN | UROGEN PHARMA LTD | 1 | 1 | 0.41% | 0.41% | 0.41% | Q3 2023 | Q3 2023 | 1 |
TROV | TROVAGENE INC | 1 | 1 | 0.40% | 0.40% | 0.40% | Q1 2015 | Q1 2015 | 1 |
ARGX | ARGENX SE | 1 | 1 | 0.40% | 0.40% | 0.40% | Q4 2017 | Q4 2017 | 1 |
VNDA | VANDA PHARMACEUTICALS INC | 1 | 1 | 0.40% | 0.40% | 0.40% | Q3 2017 | Q3 2017 | 1 |
CHTP | CHELSEA THERAPEUTICS I... | 1 | 1 | 0.34% | 0.34% | 0.34% | Q4 2013 | Q4 2013 | 1 |
BCYC | BICYCLE THERAPEUTICS P... | 1 | 1 | 0.32% | 0.32% | 0.32% | Q3 2023 | Q3 2023 | 1 |
SNMX | SENOMYX INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q2 2013 | Q2 2013 | 1 |
MRUS | MERUS N V | 1 | 1 | 0.26% | 0.26% | 0.26% | Q2 2016 | Q2 2016 | 1 |
MORF | MORPHIC HLDG INC | 1 | 1 | 0.24% | 0.24% | 0.24% | Q1 2022 | Q1 2022 | 1 |
MARINUS PHARMACEUTICAL... | 1 | 1 | 0.22% | 0.22% | 0.22% | Q4 2020 | Q4 2020 | 1 | |
ALVR | ALLOVIR INC | 1 | 1 | 0.21% | 0.21% | 0.21% | Q1 2022 | Q1 2022 | 1 |
PRQR | PROQR THERAPEUTICS N V | 1 | 1 | 0.21% | 0.21% | 0.21% | Q1 2021 | Q1 2021 | 1 |
FSDC | FS DEV CORP | 1 | 1 | 0.20% | 0.20% | 0.20% | Q3 2020 | Q3 2020 | 1 |
CATABASIS PHARMACEUTIC... | 1 | 1 | 0.20% | 0.20% | 0.20% | Q2 2021 | Q2 2021 | 1 | |
ONTY | ONCOTHYREON INC | 1 | 1 | 0.19% | 0.19% | 0.19% | Q1 2015 | Q1 2015 | 1 |
CMPS | COMPASS PATHWAYS PLC | 1 | 1 | 0.19% | 0.19% | 0.19% | Q3 2023 | Q3 2023 | 1 |
RACA | THERAPEUTICS ACQUISITI... | 1 | 1 | 0.18% | 0.18% | 0.18% | Q2 2021 | Q2 2021 | 1 |
TZYM | TRANZYME INC | 1 | 1 | 0.17% | 0.17% | 0.17% | Q2 2013 | Q2 2013 | 1 |
SENS | SENSEONICS HLDGS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q3 2019 | Q3 2019 | 1 |
CDXS | CODEXIS INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q3 2014 | Q3 2014 | 1 |
OXBT | OXYGEN BIOTHERAPEUTICS... | 1 | 1 | 0.13% | 0.13% | 0.13% | Q2 2014 | Q2 2014 | 1 |
BNTC | BENITEC BIOPHARMA LTD | 1 | 1 | 0.12% | 0.12% | 0.12% | Q3 2015 | Q3 2015 | 1 |
QURE | UNIQURE NV | 1 | 1 | 0.12% | 0.12% | 0.12% | Q1 2020 | Q1 2020 | 1 |
VRTX | VERTEX PHARMACEUTICALS... | 1 | 1 | 0.12% | 0.12% | 0.12% | Q3 2014 | Q3 2014 | 1 |
CLVS | CLOVIS ONCOLOGY INC | 1 | 1 | 0.12% | 0.12% | 0.12% | Q2 2015 | Q2 2015 | 1 |
INCY | INCYTE CORP | 1 | 1 | 0.11% | 0.11% | 0.11% | Q2 2015 | Q2 2015 | 1 |
MGTA | MAGENTA THERAPEUTICS INC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q3 2022 | Q3 2022 | 1 |
MGEN | MIRAGEN THERAPEUTICS INC | 1 | 1 | 0.10% | 0.10% | 0.10% | Q4 2020 | Q4 2020 | 1 |
FLDM | STANDARD BIOTOOLS INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2022 | Q2 2022 | 1 |
TERN | TERNS PHARMACEUTICALS INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2022 | Q2 2022 | 1 |
BCAB | BIOATLA INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2022 | Q2 2022 | 1 |
ARPO | AERPIO PHARMACEUTICALS... | 1 | 1 | 0.07% | 0.07% | 0.07% | Q2 2021 | Q2 2021 | 1 |
UNICYCIVE THERAPEUTICS... | 1 | 1 | 0.06% | 0.06% | 0.06% | Q3 2023 | Q3 2023 | 1 | |
PROF | PROFOUND MEDICAL CORP | 1 | 1 | 0.06% | 0.06% | 0.06% | Q4 2020 | Q4 2020 | 1 |
NTLA | INTELLIA THERAPEUTICS INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2021 | Q2 2021 | 1 |
VCEL | VERICEL CORP | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2020 | Q1 2020 | 1 |
EDGE | EDGE THERAPEUTICS INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2018 | Q1 2018 | 1 |
IMUX | IMMUNIC INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q4 2022 | Q4 2022 | 1 |
CTIC | CTI BIOPHARMA CORP | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2018 | Q1 2018 | 1 |
APTX | APTINYX INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2022 | Q3 2022 | 1 |
AVRO | AVROBIO INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2022 | Q2 2022 | 1 |
CLBS | CALADRIUS BIOSCIENCES | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2022 | Q2 2022 | 1 |
Download |
The securities at the top of the list , including ASCENDIS PHARMA A/S - ADR, WAVE LIFE SCIENCES PTE LTD, and TG THERAPEUTICS INC, are the highest-conviction holdings of RA Capital Management.
The conviction is calculated by counting the number of quarters a security has been reported by RA Capital Management. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that RA Capital Management owns currently or has owned in the past.